Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis

Mírian Romitti,1a Vitor C Fabris,2a Patricia K. Ziegelmann,3 Ana Luiza Maia1 and Poli Mara Spritzer2

1Thyroid Unit and 2Gynecological Endocrinology Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; 3Postgraduate Program in Epidemiology and Department of Statistics, Institute of Mathematics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

a These authors contributed equally to this work.

Corresponding author

Poli Mara Spritzer
Division of Endocrinology, Hospital de Clínicas de Porto Alegre
Rua Ramiro Barcelos, 2350
90035 003 – Porto Alegre, RS, Brazil
Phone: +55 51 33598027 / Fax: +55 51 33598777
E-mail: spritzer@ufrgs.br
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder affecting women of reproductive age. PCOS has been associated with distinct metabolic and cardiovascular diseases and with autoimmune conditions, predominantly autoimmune thyroid disease (AITD). AITD has been reported in 18-40% of PCOS women, depending on PCOS diagnostic criteria and ethnicity. The aim of this systematic review and meta-analysis was to summarize the available evidence regarding the likelihood of women with PCOS also having AITD in comparison to a reference group of non-PCOS women. We systematically searched EMBASE and MEDLINE for non-interventional case control, cross-sectional, or cohort studies published until August 2017. The Ottawa–Newcastle Scale was used to assess the methodological quality of studies. Statistical meta-analysis was performed with R. Thirteen studies were selected for the present analysis, including 1,210 women diagnosed with PCOS and 987 healthy controls. AITD was observed in 26.03% and 9.72% of PCOS and control groups respectively. A significant association was detected between PCOS and chance of AITD (OR= 3.27, 95%CI 2.32–4.63). Notably, after geographical stratification, the higher risk of AITD in PCOS women persisted for Asians (OR= 4.56, 95%CI 2.47–8.43), Europeans (OR= 3.27, 95%CI 2.07–5.15), and South Americans (OR= 1.86, 95%CI 1.05–3.29). AIDT is a frequent condition in PCOS patients, and might affect thyroid function. Thus, screening for thyroid function and thyroid-specific autoantibodies should be considered in patients with PCOS even in the absence of overt symptoms. This systematic review and meta-analysis is registered in PROSPERO under number CRD42017079676.

Keywords: PCOS, Autoimmune Thyroid Disease, TSH, systematic review, meta-analysis
Introduction

Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting women of reproductive age. The worldwide prevalence of PCOS ranges from 9 to 19.9%, depending on population characteristics and diagnostic criteria (1-5). Diagnosis of this complex multifactorial disease is based on the presence of two out of three of the following: clinical and/or biochemical androgen excess, anovulation, and polycystic ovaries on pelvic ultrasound. The mechanisms underlying individual susceptibility to PCOS include hyperinsulinemia, disruption of the hypothalamic-pituitary-gonadal axis, dysregulation of ovarian steroidogenesis, low-grade chronic inflammation (6), and genetic and environmental factors (7-9). PCOS has also been associated with type 2 diabetes, insulin resistance, obesity, dyslipidemia, hypertension, and metabolic syndrome, suggesting a contribution of the syndrome to cardiovascular risk (10-15).

The association between inflammation and autoimmunity in women with PCOS has been extensively discussed in recent years (16). Chronic low-grade inflammation might be a relevant connecting link between obesity and metabolic manifestations in PCOS (6, 17). After detecting antiovarian autoantibodies localized to the granulosa cells in women with PCOS, Van Gelderen et al. suggested a role of stimulating ovarian antibodies in PCOS pathophysiology (18). However, the concept of an autoimmune etiology is not supported by other studies describing similar prevalence of antiovarian autoantibodies in women with PCOS and controls (19), leading to the proposal of systemic immune activation by nonorgan-specific autoantibodies in PCOS (20). This could explain the recurrent association between PCOS and autoimmune diseases (21, 22) and especially autoimmune thyroid diseases (AITD), the most common form of autoimmune disorder, with an estimated prevalence of 5% (23-25).
AITD results from a dysregulation of the immune system that produces an immune attack with consequent chronic inflammation of the thyroid gland. It is classified as a T cell-mediated organ-specific autoimmune disorder (26). Affected individuals are usually positive for thyroid peroxidase (TPOAbs) and/or thyroglobulin (TgAbs) antibodies, with a typical hypoecho genic pattern at ultrasonography (27, 28). AITD is regarded as the most frequent cause of hypothyroidism in young women. Nevertheless, detectable antibodies may be observed for years without overt thyroid dysfunction. Hence, AITD often goes unnoticed until the onset of hypothyroidism later in life (29). Furthermore, a recent meta-analysis has demonstrated that the presence of subclinical hypothyroidism in PCOS women produces mild metabolic abnormalities, affecting the levels of high-density lipoprotein (HDL), triglyceride, and homeostatic model assessment for insulin resistance (HOMA-IR) (30).

To date, several studies evaluating the association between AITD and PCOS have been published without reaching a clear conclusion. A previous meta-analysis assessed the relationship between PCOS and some of its features and thyroiditis. That article included six studies, three of which were meta-analyzed to assess the prevalence of thyroiditis among women with PCOS. The results suggested a higher incidence of thyroiditis in PCOS than in controls (31). Therefore, the aim of this systematic review and meta-analysis was to summarize and update the available evidence regarding the likelihood of women with PCOS also having AITD in comparison to a reference group of women without PCOS.

Methods

Search Strategy and Study Selection
EMBASE and MEDLINE databases were searched for studies published until August 2017. No other limits except for the end date were established for the search. The protocol for this systematic review and meta-analysis is registered in PROSPERO (http://www.crd.york.ac.uk/PROSPERO/) under number CRD42017079676. Medical subject headings (MeSH) used in the search are presented as supplementary data.

The research question was developed using the PICOS strategy: the population (P) was defined as women in menopause; the intervention (I) was defined as diagnosis of PCOS; the comparison group (C) corresponded to women without PCOS; the outcome (O) was defined as autoimmune thyroid disease (AITD); and the study design (S) was defined to include non-interventional case control, cross-sectional, or cohort studies. This review had no year or language restrictions.

In case multiple reports of the same study were identified, the most complete report was chosen. If the abstracts did not provide enough information about inclusion and exclusion criteria, the full text was retrieved for evaluation.

**Data Extraction and Quality Control**

Two investigators (M.R. and V.C.F.) independently reviewed the titles and abstracts of all articles identified in the initial search to assess eligibility of the studies for inclusion in this systematic review and meta-analysis. The selected articles were read in full for confirmation of eligibility and data extraction. In case of disagreement, a third reviewer (P.M.S.) was consulted. The following information was extracted from each study: name of first author, publication year, country, number of subjects in case and control groups, age, body mass index (BMI), and
number of patients with AITD (according to the diagnostic criteria for AITD described in the study) and serum levels of thyroid-stimulating hormone (TSH).

The Newcastle-Ottawa Scale (NOS) (Retrieved August, 2017, from: www.ohri.ca/programs/clinical_epidemiology/oxford.asp) was used to assess the quality of the studies included in the meta-analysis. The NOS uses a “star system” to judge the included studies in three broad perspectives: selection of the study groups, comparability of those groups, and ascertainment of outcome of interest.

**Statistical Analysis**

Odds ratios (ORs) were used to measure the association between diagnostic status (PCOS or healthy) and AITD. ORs were pooled by the Mantel and Haenszel method using a random effects model with Der Simonian and Laird’s estimator. The Mantel–Haenszel method is more appropriate when using OR because it provides interval estimates with greater precision than those produced by the conventional inverse variance method. I² statistics and the Cochran Q test were used to assess heterogeneity among studies. Subgroup metanalysis (considering region of the study) and meta-regression (considering year of publication and total sample size) were also performed to investigate the heterogeneity among studies. All statistical tests were two-tailed. Significance was defined as $p<0.05$. Statistical analyses were performed with R version 3.2.1.

**Results**

**Study Selection**

The primary literature search identified 811 articles. After title and abstract screening, 20 studies were retrieved for full-text review. Of these, three were excluded because the full text
version could not be retrieved. A fourth study was excluded for not having a full text version (only a conference abstract had been published). Finally, three additional studies were excluded because data regarding the number or percentage of AITD individuals in each study group (PCOS and controls) was not provided. Therefore, 13 studies were included in the systematic review and meta-analysis (Figure 1).

**Characteristics of the Included Studies**

A summary of the main characteristics of the 13 studies included in the systematic review and meta-analysis is described in Table 1. Seven studies focused on Asian populations: three were performed with Turkish women (32-34), three with women from India (35-37), and one with Chinese women (38). Four studies in Europe evaluated German (39), Italian (40), Bulgarian (41), and Slovakian (42) women. Another two studies were performed in Brazilian (43) and Argentinian (44) populations. All studies employed the 2003 Rotterdam criteria for diagnosis of PCOS. AITD diagnosis was based on the criteria defined in each study. Regarding design, there were nine cross-sectional studies (32-34, 37, 39-43) and four case-control studies (35, 36, 38, 44). Population size ranged from 22 to 175 patients, totaling 1,210 women with PCOS and 987 healthy controls. In nine studies, age-matched women were selected for inclusion in the comparison group (32, 34-37, 39, 40, 42, 44), whereas three studies included healthy age-matched and BMI-matched controls (33, 38, 41). In one study, controls were described only as healthy women, without further specification (43). The mean age of PCOS participants ranged from 22 to 30.23 years, vs. 20.5 to 33.5 years in comparison groups. Mean BMI ranged from 24.6 to 34.8 kg/m$^2$ in PCOS and 21.3 to 29.2 kg/m$^2$ in comparison groups (Table 1). NOS score
was 9 in six studies (33, 37, 38, 40, 41, 44), 8 in six studies (32, 34-36, 39, 42), and 7 in one study (43) (Table 2).

**Main Results**

AITD was detected in 315 (26.03%) out of 1,210 PCOS women and in 96 (9.72%) out of 987 healthy controls. Geographical stratification revealed the presence of AITD in 28.91%, 21.8%, and 26.57% of PCOS patients and in 8.59%, 7.82% and 20.51% of healthy women from Asia, Europe, and South America respectively. Figure 2 shows the individual and pooled odds ratios (ORs) for associations between PCOS and risk of AITD. Overall, a significant association was observed between PCOS and the presence of AITD (OR = 3.27, 95%CI 2.32-4.63; P<0.0001). After geographical stratification, the higher chance of AITD in PCOS persisted for Asians (OR = 4.56, 95%CI 2.47-8.43), Europeans (OR = 3.27, 95%CI 2.07-5.15), and South Americans (OR = 1.86, 95%CI 1.05-3.29); however, the difference between subgroups was not statistically significant (P=0.0987).

Between-study heterogeneity was $I^2=39\%$ (P=0.07). Subgroup analysis by geographic region accounted for 10.81% of this heterogeneity, although statistical significance was not reached (P=0.20). Meta-regression showed that neither year of publication nor total sample size contributed to the observed heterogeneity (<0.1%) (Supplementary Figure).

Table 3 describes TSH levels in PCOS and comparison groups. Heterogeneous findings were obtained: six studies demonstrated higher TSH levels in PCOS women compared to the control group (p<0.05) (33, 37-39, 43, 44). Conversely, five studies did not find a significant difference (p>0.05) (32, 34-36, 41) between women with PCOS and controls, and one study did not provide TSH data (40). Further analyses were not performed because of the limited amount
of data regarding clinical characteristics of PCOS patients with or without AITD in the studies that were selected for analysis.

**Discussion**

In the present systematic review and meta-analysis, PCOS patients from different populations presented higher likelihood of AIDT compared to controls (OR = 3.27, 95%CI 2.32-4.63). Of note, higher risk of AIDT was detected in Asian populations (OR = 4.56, 95%CI 2.47-8.43). However, such differences among the regions were not explained by specific risk factors. Also, there is evidence that thyroid autoimmunity occurs across the world without geographic differences (45). In this sense, the differences in AIDT frequency among the studies could be attributed to variations in AIDT diagnostic criteria and in the size of studied groups.

While thyroid disorders and PCOS are among the most common endocrine conditions in the general population, the pathophysiological pathway connecting these two disorders has not been clearly established. The mechanism driving the autoimmune attack to the thyroid is complex and includes predominantly genetic, gender-associated, and environmental factors such as iodine supply, drugs, infections, and chemicals (26, 46). Likewise, the etiology of PCOS is suggested to involve genetic, ovarian-related, and other hormonal and metabolic factors such as insulin resistance/compensatory hyperinsulinemia (47). However, a common genetic background has not yet been established.

Abnormal interactions between thyrocytes, antigen-presenting cells, and T cells, along with environmental and hormonal factors are found in thyroid disease, producing disturbances in the normal balance between type 1 helper (TH1) and type 2 helper (TH2) lymphocyte immune response. More specifically, TH1-mediated autoimmunity leads to the lysis of thyrocytes and
autoimmune hypothyroidism (Hashimoto’s thyroiditis), whereas stimulatory TH2 responses against the TSH receptor lead to hyperthyroidism (Grave’s disease) (48). PCOS is characterized by androgen excess, which has been shown to be associated with reduction of most immune system elements, enhancement of T suppressor cell activity, promotion of TH1 response, and activation of CD8+ (49). In addition, progesterone levels may inhibit macrophage proliferation, IL6 synthesis, and peripheral antibody production (50). Also, *in vivo* and *in vitro* data indicate that progesterone has some capacity to suppress CD4+T cell proliferation and TH1 response (51). Indeed, PCOS women often present anovulatory cycles with low luteal phase progesterone levels and higher estrogen-to-progesterone ratio, which may increase their susceptibility to autoimmune disorders. This increased susceptibility may be due, at least in part, to the stimulatory action of estrogens on the immune system (39, 50). In turn, while studies suggest that androgens could provide protection against autoimmune disease, androgen influence on the immune system at the levels observed in PCOS is probably insufficient to prevent autoimmunity (46).

High levels of circulating IFN-γ-inducible protein 10 (IP-10/CXCL10) have been shown in patients with AITD, especially in association with a hypoechoic ultrasonographic pattern, which is a sign of a more severe lympho-monocytic infiltration and hypothyroidism (52). In fact, CXCL10 has been suggested as a marker of a stronger and more aggressive inflammatory response in the thyroid, subsequently leading to thyroid destruction and hypothyroidism (26). Interestingly, a recent study has shown that serum CXCL10 concentrations are increased in women with PCOS, which appears to be correlated with the inflammatory and insulin resistance status of PCOS (53).
The most obvious connection between thyroid diseases and PCOS seems to be an increase in BMI and insulin resistance found in both conditions. Increased BMI is very prevalent in women with PCOS, observed in 54-68% of cases (54). Interestingly, although the pathophysiological mechanisms linking thyroid function and obesity have not been clearly established, evidence indicates that TSH is higher in people with high BMI (55, 56). In contrast, recent data have shown that thyroid autoimmunity was not associated with BMI, though a connection with leptin and obesity has been suggested (57, 58). In the present meta-analysis, only three out of 13 studies included a BMI-matched control group (33, 38, 41), and higher BMI was found in PCOS compared to controls in most of the studies (32, 34, 36, 39, 42-44). However, the three studies that stratified PCOS patients with and without AIDT did not observe significant differences in BMI, indicating a lack of association between BMI and AIDT in PCOS women (39, 40, 44).

According to large epidemiological surveys, AIDT is the most frequent cause of hypothyroidism in the adult population (59-62). Clinical disease involves a variety of manifestations ranging from simple presence of thyroid antibodies (Tabs) in euthyroid patients to severe thyroid dysfunction. Most often, a euthyroid phase is followed by subclinical hypothyroidism (SCH), which slowly progresses to overt hypothyroidism (24). Subclinical hypothyroidism is frequently observed among women with PCOS, with an estimated prevalence range of 10% to 25% (63). Regarding the impact of subclinical hypothyroidism on the clinical, hormonal, or metabolic phenotype of women with PCOS, a recent meta-analysis has shown that the coexistence of SCH and PCOS leads to mild alterations in serum lipids and HOMA-IR, but not in hormone levels (SHBG, FSH, LH and their ratio). These mild changes are not clinically relevant in the short term. The long-term impact of these alterations regarding morbidity has not
been established (30). In this sense, further studies searching for the prevalence of PCOS in women with autoimmune thyroid disease could add some additional information regarding the association between these two conditions.

One strength of the present systematic review and meta-analysis is that all studies considered the Rotterdam criteria to diagnose PCOS, ensuring a homogeneous PCOS population. One limitation concerns the fact that AITD diagnosis was assessed according to the authors’ chosen criteria. Moreover, because the studies did not provide this information, we were unable to evaluate the differences in TSH levels between PCOS women with or without AITD. The same was true for other clinical characteristics, which were not reported and therefore precluded further comparisons between the two groups. Another limitation is that, despite the absence of significant heterogeneity among studies from different geographical regions, there were limited data from Western European countries and the US. Due to these limitations, the present data should be interpreted with caution.

In conclusion, the present systematic review and meta-analysis provides evidence of higher prevalence of AITD in patients with PCOS compared to healthy controls. Therefore, physicians should consider screening for thyroid function and thyroid-specific autoantibodies at PCOS diagnosis, even in the absence of symptoms related with thyroid dysfunction.

Declaration of interest

The authors declare no competing interests.

Funding
This work was supported by the Brazilian National Institute of Hormones and Women’s Health/ Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq INCT 465482/2014-7) and Fundação de Amparo à Pesquisa do Rio Grande do Sul (FAPERGS INCT 17/2551-0000519-8).
References


42. Petrikova J, Lazurova I, Dravecka I, Vrbikova J, Kozakova D, Figurova J, Vaczy Z, Rosocha J. The prevalence of non organ specific and thyroid autoimmunity in patients with polycystic ovary syndrome. *Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia* 2015; **159**: 302-6.


47. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. *Endocrine reviews* 2010; **31**: 702-55.


Figure Legends

Figure 1 PRISMA flow diagram of the study selection process

Figure 2 Forest plot showing individual and pooled odds ratios for presence of AITD in women with PCOS in different populations

Supplementary Figure Meta-regression of factors that could influence on the heterogeneity between studies. A) sample size and B) year of publication
### Characteristics of studies included in systematic review and meta-analysis investigating the association between polycystic ovary syndrome and autoimmune thyroid disease

<table>
<thead>
<tr>
<th>Country</th>
<th>Type of study</th>
<th>Comparison group</th>
<th>PCOS</th>
<th>Comparison Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n</td>
<td>Age (mean±SD)</td>
<td>BMI (mean±SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkey</td>
<td>Cross-sectional</td>
<td>Age-matched women without PCOS</td>
<td>73</td>
<td>22 (18–37)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age-matched women without PCOS</td>
<td>55</td>
<td>23.27±3.2</td>
</tr>
<tr>
<td></td>
<td>Case-control</td>
<td>Age-matched healthy women</td>
<td>60</td>
<td>20.50 (19–35)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age-matched healthy women</td>
<td>80</td>
<td>22.7±5.30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age-matched healthy women</td>
<td>90</td>
<td>30.02±8.51</td>
</tr>
<tr>
<td></td>
<td>Case-control</td>
<td>Age-matched healthy women</td>
<td>97</td>
<td>24.1±6.0</td>
</tr>
<tr>
<td>Germany</td>
<td>Cross-sectional</td>
<td>Age-matched women without PCOS</td>
<td>17</td>
<td>28±6.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age-matched healthy women</td>
<td>11</td>
<td>24±6.3</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Cross-sectional</td>
<td>Age and BMI-matched healthy women</td>
<td>70</td>
<td>25.06±0.69</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age and BMI-matched healthy women</td>
<td>64</td>
<td>30.23±6.7</td>
</tr>
<tr>
<td>Slovakia</td>
<td>Cross-sectional</td>
<td>Women without PCOS</td>
<td>65</td>
<td>27.8±6.9</td>
</tr>
<tr>
<td>Argentina</td>
<td>Case-control</td>
<td>Age-matched healthy women</td>
<td>14</td>
<td>24.5±6.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age-matched healthy women</td>
<td>17</td>
<td>28±6.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age-matched healthy women</td>
<td>11</td>
<td>24±6.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age and BMI-matched healthy women</td>
<td>70</td>
<td>25.06±0.69</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age and BMI-matched healthy women</td>
<td>64</td>
<td>30.23±6.7</td>
</tr>
<tr>
<td></td>
<td>Case-control</td>
<td>Age-matched healthy women</td>
<td>14</td>
<td>24.5±6.7</td>
</tr>
</tbody>
</table>

PCOS: Polycystic Ovary Syndrome; AITD: Autoimmune Thyroid Disease; SD: Standard Deviation; TPO: Thyroid peroxidase; Tg: Thyroglobulin; TSH: Thyroid-Stimulating Hormone; NA: Not Available. * Median (Minimum and Maximum)
## Table 2. Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Selection</th>
<th>Comparability</th>
<th>Outcome</th>
<th>Total Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duran et al., 2014 (31)</td>
<td>★★★★☆</td>
<td>★</td>
<td>★★★★☆</td>
<td>8</td>
</tr>
<tr>
<td>Arduc et al., 2015 (32)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>9</td>
</tr>
<tr>
<td>Arora et al., 2015 (34)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>8</td>
</tr>
<tr>
<td>Menon et al., 2016 (35)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>8</td>
</tr>
<tr>
<td>Yu et al., 2016 (37)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>9</td>
</tr>
<tr>
<td>Sinha et al., 2017 (36)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>9</td>
</tr>
<tr>
<td>Karakose et al., 2017 (33)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>8</td>
</tr>
<tr>
<td>Janssen et al., 2004 (38)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>8</td>
</tr>
<tr>
<td>Garelli et al., 2013 (39)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>9</td>
</tr>
<tr>
<td>Miklov et al., 2015 (40)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>9</td>
</tr>
<tr>
<td>Petrikova et al., 2015 (41)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>8</td>
</tr>
<tr>
<td>Novais et al., 2014 (42)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>7</td>
</tr>
<tr>
<td>Calvar et al., 2015 (43)</td>
<td>★★★★☆</td>
<td>★☆</td>
<td>★★★★☆</td>
<td>9</td>
</tr>
</tbody>
</table>
Table 3. Studies comparing TSH levels in PCOS and control groups

<table>
<thead>
<tr>
<th>Author, year</th>
<th>TSH (mean ± SD)</th>
<th>Comparison group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duran et al., 2014 (32)</td>
<td>2.09 (0.67–16.51)*</td>
<td>1.96 (0.01–7.08)*</td>
<td>P=0.397</td>
</tr>
<tr>
<td>Arduc et al., 2015 (33)</td>
<td>2.9 (0.20–17.9)*</td>
<td>1.8 (0.31–5.4)*</td>
<td>P=0.037</td>
</tr>
<tr>
<td>Arora et al., 2015 (35)</td>
<td>3.17±2.74</td>
<td>2.98±2.18</td>
<td>P=0.70</td>
</tr>
<tr>
<td>Menon et al., 2016 (36)</td>
<td>5.99±1.8</td>
<td>8.09±2.4</td>
<td>P=0.50</td>
</tr>
<tr>
<td>Yu et al., 2016 (38)</td>
<td>5.11±22.7</td>
<td>2.9±3.2</td>
<td>P=0.70</td>
</tr>
<tr>
<td>Sinha et al., 2017 (37)</td>
<td>4.547±2.66</td>
<td>2.67±3.11</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Karakose et al., 2017 (34)</td>
<td>2.4±1.2</td>
<td>2.0±1.0</td>
<td>P=0.243</td>
</tr>
<tr>
<td>Janssen et al., 2004 (39)</td>
<td>2.0±1.0</td>
<td>1.4±0.6</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Garelli et al., 2013 (40)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Mitkov et al., 2015 (41)</td>
<td>2.46±0.25</td>
<td>1.73±0.11</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td>Petrikova et al., 2015 (42)</td>
<td>2.37±1.46</td>
<td>2.37±1.46</td>
<td>P=0.937</td>
</tr>
<tr>
<td>Novais et al., 2014 (43)</td>
<td>2.9±1.8</td>
<td>2.2±1.2</td>
<td>P=0.013</td>
</tr>
<tr>
<td>Calvar et al., 2015 (44)</td>
<td>3.4±2.8</td>
<td>1.8±0.9</td>
<td>P&lt;0.001</td>
</tr>
</tbody>
</table>

PCOS: Polycystic Ovary Syndrome; SD: Standard Deviation; TSH: Thyroid-Stimulating Hormone; NA: Not Available.
* Median (Minimum and Maximum)
Figure 1. PRISMA flow diagram of the study selection process

811 records identified through database searching

228 duplicates removed

583 records screened

314 records identified in MEDLINE

497 records identified in EMBASE

563 records excluded

Seven full-text articles excluded:
- Three because the full-text version could not be retrieved
- One had been published in abstract format only
- Three articles did not provide data on the variable of interest

20 full-text articles assessed for eligibility

13 studies included in the systematic review and meta-analysis

228 duplicates removed

583 records screened

314 records identified in MEDLINE

497 records identified in EMBASE

563 records excluded
### Study Results

#### Region = Asia

<table>
<thead>
<tr>
<th>Study</th>
<th>PCOS Events</th>
<th>PCOS Total</th>
<th>Control Events</th>
<th>Control Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duran et al. 2014 [32]</td>
<td>23</td>
<td>73</td>
<td>14</td>
<td>60</td>
<td>1.51</td>
<td>[0.70; 3.28]</td>
<td>10.2%</td>
<td></td>
</tr>
<tr>
<td>Arduc et al. 2015 [33]</td>
<td>19</td>
<td>86</td>
<td>3</td>
<td>60</td>
<td>5.39</td>
<td>[1.52; 19.14]</td>
<td>5.5%</td>
<td></td>
</tr>
<tr>
<td>Arora et al. 2015 [35]</td>
<td>21</td>
<td>55</td>
<td>8</td>
<td>51</td>
<td>3.32</td>
<td>[1.31; 8.42]</td>
<td>8.3%</td>
<td></td>
</tr>
<tr>
<td>Menon et al. 2016 [36]</td>
<td>23</td>
<td>90</td>
<td>5</td>
<td>90</td>
<td>5.84</td>
<td>[2.11; 16.16]</td>
<td>7.4%</td>
<td></td>
</tr>
<tr>
<td>Yu et al. 2016 [38]</td>
<td>25</td>
<td>100</td>
<td>2</td>
<td>100</td>
<td>16.33</td>
<td>[3.75; 71.13]</td>
<td>4.4%</td>
<td></td>
</tr>
<tr>
<td>Karakose et al. 2017 [34]</td>
<td>39</td>
<td>97</td>
<td>11</td>
<td>71</td>
<td>3.67</td>
<td>[1.71; 7.84]</td>
<td>10.4%</td>
<td></td>
</tr>
<tr>
<td>Sinha et al. 2017 [37]</td>
<td>18</td>
<td>80</td>
<td>1</td>
<td>80</td>
<td>22.94</td>
<td>[2.98; 176.55]</td>
<td>2.5%</td>
<td></td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>581</strong></td>
<td><strong>512</strong></td>
<td></td>
<td></td>
<td><strong>4.56</strong></td>
<td><strong>[2.47; 8.43]</strong></td>
<td><strong>48.7%</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $I^2 = 56\%$, $\tau^2 = 0.3628$, $p = 0.03$

#### Region = Europe

<table>
<thead>
<tr>
<th>Study</th>
<th>PCOS Events</th>
<th>PCOS Total</th>
<th>Control Events</th>
<th>Control Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen et al. 2004 [39]</td>
<td>36</td>
<td>175</td>
<td>11</td>
<td>168</td>
<td>3.70</td>
<td>[1.81; 7.54]</td>
<td>11.0%</td>
<td></td>
</tr>
<tr>
<td>Garelli et al. 2013 [40]</td>
<td>30</td>
<td>113</td>
<td>8</td>
<td>100</td>
<td>4.16</td>
<td>[1.80; 9.57]</td>
<td>9.4%</td>
<td></td>
</tr>
<tr>
<td>Milkov et al. 2015 [41]</td>
<td>14</td>
<td>70</td>
<td>2</td>
<td>22</td>
<td>2.50</td>
<td>[0.52; 11.98]</td>
<td>4.0%</td>
<td></td>
</tr>
<tr>
<td>Petrikova et al. 2015 [42]</td>
<td>12</td>
<td>64</td>
<td>7</td>
<td>68</td>
<td>2.01</td>
<td>[0.74; 5.48]</td>
<td>7.6%</td>
<td></td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>422</strong></td>
<td><strong>358</strong></td>
<td></td>
<td></td>
<td><strong>3.27</strong></td>
<td><strong>[2.07; 5.15]</strong></td>
<td><strong>32.0%</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.69$

#### Region = South America

<table>
<thead>
<tr>
<th>Study</th>
<th>PCOS Events</th>
<th>PCOS Total</th>
<th>Control Events</th>
<th>Control Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novais et al. 2014 [43]</td>
<td>28</td>
<td>65</td>
<td>17</td>
<td>65</td>
<td>2.14</td>
<td>[1.02; 4.48]</td>
<td>10.7%</td>
<td></td>
</tr>
<tr>
<td>Calvar et al. 2015 [44]</td>
<td>27</td>
<td>142</td>
<td>7</td>
<td>52</td>
<td>1.51</td>
<td>[0.61; 3.71]</td>
<td>8.6%</td>
<td></td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>207</strong></td>
<td><strong>117</strong></td>
<td></td>
<td></td>
<td><strong>1.86</strong></td>
<td><strong>[1.05; 3.29]</strong></td>
<td><strong>19.3%</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.56$

**Random effects model**

<table>
<thead>
<tr>
<th>Events</th>
<th>Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PCOS</strong></td>
<td><strong>1210</strong></td>
<td><strong>3.27</strong></td>
<td><strong>[2.32; 4.63]</strong></td>
<td><strong>100.0%</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $I^2 = 39\%$, $\tau^2 = 0.1506$, $p = 0.07$
Medical subject headings (MeSH) used in the search

The following medical subject headings (MeSH) were used in the search:

(Polycystic Ovarian Syndrome OR Ovary Syndrome, Polycystic OR Syndrome,
Polycystic Ovary OR Stein-Leventhal Syndrome OR Stein Leventhal Syndrome OR
Syndrome, Stein-Leventhal OR Sclerocystic Ovarian Degeneration OR Ovarian
Degeneration, Sclerocystic OR Sclerocystic Ovary Syndrome OR Ovarian Syndrome,
Polycystic OR Polycystic Ovary Syndrome 1 OR Sclerocystic Ovaries OR Ovary,
Sclerocystic OR Sclerocystic Ovary OR PCOS) AND (Autoimmune Thyroiditis OR
Thyroiditis, Autoimmune OR Autoimmune Thyroiditis OR Thyroiditis, Lymphocytic
OR Lymphocytic Thyroiditis OR Lymphocytic Thyroiditis OR Thyroiditis,
Lymphocytic OR Thyroiditis, Lymphomatous OR Lymphomatous Thyroiditis OR
Lymphomatous Thyroiditis OR Thyroiditis, Lymphomatous OR Disease, Hashimoto
OR Hashimoto Struma OR Hashimoto Thyroiditis OR Hashimoto Thyroiditis OR
Thyroiditis, Hashimoto OR Thyroiditis, Hashimoto OR Hashimoto's Syndrome OR
Hashimoto Syndrome OR Hashimoto's Syndromes OR Hashimoto’s Syndrome OR
Syndrome, Hashimoto's OR Syndromes, Hashimoto's OR Hashimoto's Struma OR
Chronic Lymphocytic Thyroiditis OR Chronic Lymphocytic Thyroiditis OR
Lymphocytic Thyroiditis, Chronic OR Lymphocytic Thyroiditis, Chronic OR
Thyroiditis, Chronic Lymphocytic OR Thyroiditis, Chronic Lymphocytic OR
Hashimoto's Disease OR Disease, Hashimoto’s OR Hashimoto’s Disease).
A \[ \text{Ln(OR)} = 0.8 + 0.0022 \times \text{Sample size}, \ p = 0.41 \]

B \[ \text{Ln(OR)} = -28 + 0.015 \times \text{Year of publication}, \ p = 0.77 \]